Literature DB >> 20080069

Myeloperoxidase-dependent oxidative metabolism of nitric oxide in the cystic fibrosis airway.

Anna L P Chapman1, Brian M Morrissey, Vihas T Vasu, Maya M Juarez, Jessica S Houghton, Chin-Shang Li, Carroll E Cross, Jason P Eiserich.   

Abstract

BACKGROUND: Decreased expired nitric oxide (eNO) is commonly observed in cystic fibrosis (CF) patients and is usually explained by dysregulation of NO synthase (NOS) isoforms in respiratory tract epithelium. Later stages of this disease are accompanied by intense airway infiltration of phagocytes with high NOS activity, abundant levels of the hemoprotein myeloperoxidase (MPO) and significant production of significant reactive oxygen species.
METHODS: This study characterizes the contribution of the high airway levels of MPO to decreased eNO levels in adult CF patients. NO metabolites (NO(x)) and MPO levels in fresh sputum of control and adult CF patients were determined and related to measurements of eNO and to in vitro consumption of NO in CF sputum.
RESULTS: Despite essentially equal levels of NO(x) in sputum, eNO was 2- to 3-fold lower in CF patients compared to healthy controls. In CF patients, eNO levels were negatively associated with sputum peroxidase activity. In vivo correlations were confirmed by ex vivo studies of NO consumption by MPO in CF sputum. Immunodepletion studies confirmed MPO as the major heme peroxidase in CF sputum contributing to the hydrogen peroxide (H(2)O(2))-dependent consumption of NO.
CONCLUSIONS: In CF airways MPO acts as a phagocyte-derived NO oxidase that diminishes NO bioavailability at airway surfaces, possibly identifying this peroxidase as a potential target for therapeutic intervention. Copyright (c) 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080069      PMCID: PMC3118565          DOI: 10.1016/j.jcf.2009.10.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  48 in total

1.  The lactoperoxidase system functions in bacterial clearance of airways.

Authors:  C Gerson; J Sabater; M Scuri; A Torbati; R Coffey; J W Abraham; I Lauredo; R Forteza; A Wanner; M Salathe; W M Abraham; G E Conner
Journal:  Am J Respir Cell Mol Biol       Date:  2000-06       Impact factor: 6.914

2.  Nitric oxide is a physiological substrate for mammalian peroxidases.

Authors:  H M Abu-Soud; S L Hazen
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

3.  Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence.

Authors:  P Scheid; L Kempster; U Griesenbach; J C Davies; A Dewar; P P Weber; W H Colledge; M J Evans; D M Geddes; E W Alton
Journal:  Eur Respir J       Date:  2001-01       Impact factor: 16.671

Review 4.  Clinical aspects of exhaled nitric oxide.

Authors:  S A Kharitonov; P J Barnes
Journal:  Eur Respir J       Date:  2000-10       Impact factor: 16.671

5.  Sputum processing for evaluation of inflammatory mediators.

Authors:  J S Kim; G H Hackley; K Okamoto; B K Rubin
Journal:  Pediatr Pulmonol       Date:  2001-08

6.  Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function.

Authors:  H Grasemann; B Gaston; K Fang; K Paul; F Ratjen
Journal:  J Pediatr       Date:  1999-12       Impact factor: 4.406

7.  Myeloperoxidase and protein oxidation in cystic fibrosis.

Authors:  A Van Der Vliet; M N Nguyen; M K Shigenaga; J P Eiserich; G P Marelich; C E Cross
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-09       Impact factor: 5.464

8.  Elevation of nitrotyrosine and nitrate concentrations in cystic fibrosis sputum.

Authors:  K L Jones; A H Hegab; B C Hillman; K L Simpson; P A Jinkins; M B Grisham; M W Owens; E Sato; R A Robbins
Journal:  Pediatr Pulmonol       Date:  2000-08

9.  Nitrite as a substrate and inhibitor of myeloperoxidase. Implications for nitration and hypochlorous acid production at sites of inflammation.

Authors:  C J van Dalen; C C Winterbourn; R Senthilmohan; A J Kettle
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

10.  Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments.

Authors:  D Hubert; F Aubourg; B Fauroux; L Trinquart; I Sermet; G Lenoir; A Clément; A T Dinh-Xuan; B Louis; B Mahut; C Delclaux
Journal:  Eur Respir J       Date:  2009-02-12       Impact factor: 16.671

View more
  6 in total

1.  Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: Focus on myeloperoxidase.

Authors:  Vihas T Vasu; Sharon J de Cruz; Jessica S Houghton; Keri A Hayakawa; Brian M Morrissey; Carroll E Cross; Jason P Eiserich
Journal:  Free Radic Res       Date:  2010-10-18

2.  Withania somnifera (L.) Dunal as Add-On Therapy for COPD Patients: A Randomized, Placebo-Controlled, Double-Blind Study.

Authors:  Priyam Singh; Khushtar Anwar Salman; Mohammad Shameem; Mohd Sharib Warsi
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

3.  Concentration of the antibacterial precursor thiocyanate in cystic fibrosis airway secretions.

Authors:  Daniel Lorentzen; Lakshmi Durairaj; Alejandro A Pezzulo; Yoko Nakano; Janice Launspach; David A Stoltz; Gideon Zamba; Paul B McCray; Joseph Zabner; Michael J Welsh; William M Nauseef; Botond Bánfi
Journal:  Free Radic Biol Med       Date:  2011-02-18       Impact factor: 7.376

4.  Molecular profiling of the human nasal epithelium: A proteomics approach.

Authors:  Tânia Simões; Nuno Charro; Josip Blonder; Daniel Faria; Francisco M Couto; King C Chan; Timothy Waybright; Haleem J Isaaq; Timothy D Veenstra; Deborah Penque
Journal:  J Proteomics       Date:  2011-05-18       Impact factor: 4.044

5.  Fermented Mangosteen (Garcinia mangostana L.) Supplementation in the Prevention of HPV-Induced Cervical Cancer: From Mechanisms to Clinical Outcomes.

Authors:  Zaira Kharaeva; Pavel Trakhtman; Ilya Trakhtman; Chiara De Luca; Wolfgang Mayer; Jessie Chung; Galina Ibragimova; Liudmila Korkina
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575

6.  Application of nitric oxide measurements in clinical conditions beyond asthma.

Authors:  Andrei Malinovschi; Dora Ludviksdottir; Ellen Tufvesson; Giovanni Rolla; Leif Bjermer; Kjell Alving; Zuzana Diamant
Journal:  Eur Clin Respir J       Date:  2015-08-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.